Arbutus Biopharma (ABUS) Gains from Investment Securities (2015 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Gains from Investment Securities of $209000.0 for Q1 2026, down 30.1% year-on-year from $299000.0 in Q1 2025, and up 107.87% on a QoQ basis from -$2.7 million in Q4 2025.
Arbutus Biopharma (ABUS) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Gains from Investment Securities for 12 consecutive years, with $209000.0 the latest figure, recorded in Q1 2026.
- Quarterly Gains from Investment Securities fell 30.1% year-over-year to $209000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 169.97% YoY) and the FY2025 annual result came in at -$1.8 million, down 169.71% from the prior year.
- Gains from Investment Securities grew to $209000.0 in Q1 2026 per ABUS's latest filing, from -$2.7 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for ABUS reached as high as $1.9 million in Q4 2024 and fell as low as -$2.7 million in Q4 2025.
- A 5-year average of $194470.6 and a median of $215000.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities surged 733.68% — and 2023, when it slumped 405.77%.
- Year by year, Gains from Investment Securities stood at $1.6 million in 2022, then sank by 85.89% to $227000.0 in 2023, then surged by 732.6% to $1.9 million in 2024, then sank by 240.58% to -$2.7 million in 2025, then soared by 107.87% to $209000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $209000.0, -$2.7 million, and $227000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,000.00 |
| Mar 31, 2026 | 209,000.00 |
| Dec 31, 2025 | -2.66 Mn |
| Dec 31, 2025 | -2.66 Mn |
| Sep 30, 2025 | 227,000.00 |
| Sep 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Dec 31, 2024 | 1.89 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | 344,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Jun 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 211,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Dec 31, 2023 | 227,000.00 |